Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with FBD Biologics Limited for the exclusive rights to develop, manufacture, and commercialize the fusion protein HCB101 in specified territories including Mainland China, Hong Kong, Macao, Southeast Asia, and parts of the MENA region. This strategic partnership allows Henlius to advance its oncology pipeline with HCB101, currently in phase 1b/2a clinical trials, potentially enhancing its market positioning and offering significant growth opportunities in the biopharmaceutical sector.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative biopharmaceutical products. The company primarily targets the oncology sector, leveraging its expertise in monoclonal antibodies and fusion proteins to address unmet medical needs.
Average Trading Volume: 1,407,311
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.31B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.